Thromb Haemost 1983; 50(03): 726-730
DOI: 10.1055/s-0038-1665296
Original Article
Schattauer GmbH Stuttgart

Interaction of Human Tumor Cells with Human Platelets and the Coagulation System

Hamid Al-Mondhiry
The Divisions of Hematology and Oncology, Department of Medicine, the Pennsylvania State University, College of Medicine, the M. S. Hershey Medical Center Hershey, Pennsylvania, U.S.A.
,
Virginia McGarvey
The Divisions of Hematology and Oncology, Department of Medicine, the Pennsylvania State University, College of Medicine, the M. S. Hershey Medical Center Hershey, Pennsylvania, U.S.A.
,
Kim Leitzel
The Divisions of Hematology and Oncology, Department of Medicine, the Pennsylvania State University, College of Medicine, the M. S. Hershey Medical Center Hershey, Pennsylvania, U.S.A.
› Author Affiliations
Further Information

Publication History

Received 30 March 1983

Accepted 05 August 1983

Publication Date:
18 July 2018 (online)

Summary

This paper reports studies on the interaction between human platelets, the plasma coagulation system, and two human tumor cell lines grown in tissue culture: Melanoma and breast adenocarcinoma. The interaction was monitored through the use of 125I- labelled fibrinogen, which measures both thrombin activity generated by cell-plasma interaction and fibrin/fibrinogen binding to platelets and tumor cells. Each tumor cell line activates both the platelets and the coagulation system simultaneously resulting in the generation of thrombin or thrombin-like activity. The melanoma cells activate the coagulation system through “the extrinsic pathway” with a tissue factor-like effect on factor VII, but the breast tumor seems to activate factor X directly. Both tumor cell lines activate platelets to “make available” a platelet- derived procoagulant material necessary for the conversion of prothrombin to thrombin. The tumor-derived procoagulant activity and the platelet aggregating potential of cells do not seem to be inter-related, and they are not specific to malignant cells.

 
  • References

  • 1 Gralnick HR. Cancer cell procoagulant activity. In: Donati MB, Davidson JF, Garattini S. (eds) Malignancy and the hemostatic system. Raven Press; New York: 1981. p 57
  • 2 Gouault-Heilmann M, Chardon E, Sultan C, Josso F. The procoagulant factor of leukemic promyelocytes. Demonstration of immunologic cross reactivity with human brain tissue factor Br J Haematol 1975; 30: 151-158
  • 3 Sakuragawa N, Takahaski K, Hoshiyama M, Jimbo C, Ashizawa K, Matusuoka M, Ohnishi Y. The extract from tissue of gastric cancer as procoagulant in disseminated intravascular coagulation syndrome. Thromb Res 1977; 10: 457-463
  • 4 Pineo GF, Brain MC, Gallus AS, Hirsh J, Halton MW C, Regoeczi E. Tumors, mucous production and hypercoagulability. Ann NY Acad Sci 1974; 230: 262-270
  • 5 Gasic GJ, Gasic TM, Galanti N, Johnson T, Murphy S. Platelet- tumor cell interaction in miceThe role of platelets in the spread of malignant disease. Int J Cancer 1973; 11: 704-718
  • 6 Hilgard P. The role of platelets in experimental metastases. Br J Cancer 1973; 28: 429-435
  • 7 Gasic GJ, Gasic TB. Plasma membrane vesicles as mediators of interactions between tumor cells and components of the hemostatic and immune system. In: Jamieson GA. (ed) Interaction of platelets and tumor cells.. Alan R. Liss; New York: 1982. p 429
  • 8 Pearlstein E, Saik PL, Yogeeswaran G, Karpatkin S. Correlation between spontaneous metastatic potential, platelet aggregating activity of cell surface extracts and cell surface sialyation in 10 metastatic variant derivatives of a rat renal sarcoma cell line. Proc Natl Acad Sci USA 1980; 77: 4336-4339
  • 9 Pearlstein E, Cooper LB, Karpatkin S. Extraction and characterization of a platelet aggregating material from SV40-transformed mouse 3T3 fibroblasts. J Lab Clin Med 1979; 93: 322-344
  • 10 Karpatkin S, Pearlstein E. Role of platelets in tumor metastasis. Ann Intern Med 1981; 95: 636-641
  • 11 Jones DS, Wallace AC, Fraser EE. Sequence of events in experimental metastases of Walker 256 Tumor: Light, immuno- fluorescent and electron microscopic observations. J Natl Cancer Inst 1971; 46: 493-504
  • 12 Warren BA, Vales O. The adhesion of thromboplastic tumor emboli to vessel walls in vivo. Br J Exp Pathol 1972; 53: 301-313
  • 13 Warren BA. The ultrastructure of platelet pseudopodia and the adhesion of homologous platelets to tumor cells. Br J Exp Pathol 1970; 51: 570-580
  • 14 Warren BA. Tumor metastasis and thrombosis. In: Thrombosis: Pathogenesis and clinical trials. Deutsch E, Lechner K, Brinkhous KM, Hinnom S. (eds) Thrombos Diathes Hemorrh 1974. Suppl 59 140-156
  • 15 Thornes RD. Fibrin and Cancer. Br J Med 1972; 1: 110-111
  • 16 Lipton A, Kepner N, Rogers C, Witkoski E, Leitzel K. Microgenic factor for transformed cells from human platelets. In: Jamieson GA. (ed) Interaction of platelets and tumor cells. Alan R. Liss; New York: 1982. p 233
  • 17 Gasic GJ, Gasic TB, Murphy S. Antimetastatic effect of aspirin. Lancet 1972; 2: 932-933
  • 18 Gasic GJ, Koch PA G, Hsu B, Gasic TB, Niewiaroswski S. Thrombogenic activity of mouse and human tumors: Effect of platelets, coagulation and fibrinolysis. Z Krebs 1976; 86: 263-271
  • 19 Donati MB, Rotillio D, Delaini F, Giavazzi R, Montavani A, Poggi A. Animal model for the study of platelet-tumor cell interactions. In: Jamieson GA. (ed) Interaction of platelets and tumor cells.. Alan R. Liss; New York: 1982. p 159
  • 20 Jamieson GA, Bastida E, Ordinas A. Mechanism of platelet aggregation by human tumor cell lines. Ibid p 405
  • 21 Mohammed SF, Chuang HY K, Szakacs J, Mason RG. Isolation and partial purification of an activity from human pulmonary epidermoid carcinoma cells in culture that clots heparinized plasma. Ibid p 415
  • 22 Zacharaski LR, Handerson W, Rickies FR, Forman WB, Cornell CJ, Fortier RJ, Harrower HW, Johnson RO. Rationale and experimental design for the VA cooperative study of anticoagulation (Warfarin) in the treatment of cancer. Cancer 1979; 44: 732-741
  • 23 Tangen O, Berman HJ. Gel filtration of blood platelets: a methodological report. Adv Exp Med Biol 1972; 34: 235-243
  • 24 Margurie GA, Plow EF, Edgington TS. Human platelets possess an inducible and saturable receptor specific for fibrinogen. J Biol Chem 1979; 254: 5357-5363
  • 25 Kazal LA, Amsel S, Miller OP, Tocantis M. The preparation and some properties of fibrinogen precipitated from human plasma by glycine. Proc Soc Exp Biol Med 1963; 113: 989-994
  • 26 Bowie EJ W, Thompson JH, Didisheim P, Owen Jr CA. Mayo clinic laboratory manual of hemostasis. Appendix I W B Saunders; Philadelphia: 1971. p l61
  • 27 Greenwood FC, Hunter WM, Glover JS. The preparation of 131I-labelled human growth hormone of high specific radioactivity. Biochem J 1963; 89: 114-123
  • 28 Weber K, Osborn M. The reliability of molecular weight determination by deodecyl sulphate polyacrylamide gel electrophoresis. J Biol Chem 1969; 244: 4406-4412
  • 29 Born GV R, Cross MJ. The aggregation of blood platelets. J Physiol 1963; 168: 178-195
  • 30 Horowitz HI, Papayoanou MF. Release of nonsedimentable platelet factor 3 during coagulation. J Lab Clin Med 1967; 69: 1003-1012
  • 31 Wolf P. The nature and significance of platelet products in human plasma. Br J Haematol 1967; 13: 269-288
  • 32 Holme R, Oftebro R, Hovig T. In vitro interaction between cultured cells and human blood platelets. Thromb Haemostas 1978; 40: 89-102
  • 33 Hudig D, Bajaj P. Tissue factor-like activity in human monocytic tumor cell line U937. Thromb Res 1982; 27: 321-332
  • 34 Gordon SG, Franks JJ, Lewis B. Cancer procoagulant A: A factor X activating procoagulant from malignant tissue. Thromb Res 1975; 6: 127-137
  • 35 Marguerie GA, Edgington TS, Plow EF. Interaction of fibrinogen with its platelet receptor as a part of a multistep reaction in ADP- induced platelet aggregation. J Biol Chem 1980; 255: 154-161